Payment overview · 2025
General Payments
$2,771.32
178 reported records · 24 companies
Healthcare provider profile · identity verified
Patrick Leon Murphy, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1316384936
Verified facts
What the public records show
CMS Open Payments records show Patrick Leon Murphy, MD received $2,771.32 in general payments during 2025 across 178 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trulance, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $615.50 | 22.2% | 50 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $314.00 | 11.3% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $304.44 | 11.0% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $244.92 | 8.8% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $205.68 | 7.4% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $158.13 | 5.7% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.97 | 5.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.94 | 3.4% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.45 | 3.3% | 5 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $90.30 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.90 | 2.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.26 | 2.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.85 | 1.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $40.37 | 1.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.89 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.94 | 1.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.63 | 1.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $32.88 | 1.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.24 | 1.1% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $29.82 | 1.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.80 | 1.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.05 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.94 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.42 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,771.32 | 178 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $332.87 | 25 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $205.68 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.47 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $185.01 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $175.89 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $165.58 | 12 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $158.13 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $148.42 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.42 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.77 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.71 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.35 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $102.97 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $97.62 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.94 | 6 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $90.30 | 2 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $90.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.91 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $85.91 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.90 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.90 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.10 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.60 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.26 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $48.03 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.63 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $32.88 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.24 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $2.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 179 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 99 |
| Lisinopril | Lisinopril | 265 | 84 |
| Losartan Potassium | Losartan Potassium | 234 | 71 |
| Potassium Chloride | Potassium Chloride | 232 | 76 |
| Metformin Hcl | Metformin Hcl | 229 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 72 |
| Omeprazole | Omeprazole | 190 | 61 |
| Ozempic | Semaglutide | 179 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 53 |
| Gabapentin | Gabapentin | 155 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 42 |
| Carvedilol | Carvedilol | 143 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 42 |
| Trazodone Hcl | Trazodone Hcl | 142 | 40 |
| Celecoxib | Celecoxib | 140 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 138 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 46 |
| Meloxicam | Meloxicam | 116 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 35 |
| Allopurinol | Allopurinol | 107 | 27 |
| Spironolactone | Spironolactone | 100 | 29 |
| Simvastatin | Simvastatin | 93 | 27 |
| Alendronate Sodium | Alendronate Sodium | 92 | 33 |
| Sertraline Hcl | Sertraline Hcl | 89 | 30 |
| Eliquis | Apixaban | 86 | 24 |
| Mounjaro | Tirzepatide | 86 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Montelukast Sodium | Montelukast Sodium | 83 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 31 |
| Furosemide | Furosemide | 80 | 35 |
| Doxepin Hcl | Doxepin Hcl | 74 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 19 |
| Ondansetron Odt | Ondansetron | 70 | 27 |
| Jardiance | Empagliflozin | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 14 |
| Clonazepam | Clonazepam | 62 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 16 |
| Tramadol Hcl | Tramadol Hcl | 61 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 20 |
| Linzess | Linaclotide | 52 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 20 |
| Rybelsus | Semaglutide | 51 | 16 |
| Famotidine | Famotidine | 50 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 19 |
| Pregabalin | Pregabalin | 49 | 21 |
| Ibuprofen | Ibuprofen | 48 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 17 |
| Promethazine Hcl | Promethazine Hcl | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 40 |
| Baclofen | Baclofen | 44 | 13 |
| Chlorthalidone | Chlorthalidone | 44 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Azithromycin | Azithromycin | 43 | 40 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 21 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 13 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Valsartan | Valsartan | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Fluconazole | Fluconazole | 31 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 18 |
| Primidone | Primidone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 22 |
| Cephalexin | Cephalexin | 23 | 17 |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | suppressed |
| Prednisone | Prednisone | 20 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Finasteride | Finasteride | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Diazepam | Diazepam | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 13 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Cefaclor | Cefaclor | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,771.32 · 178 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, EGRIFTA, ENTRESTO, EVENITY, FARXIGA, FUROSCIX, GEMTESA, IBSRELA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Qelbree, RELISTOR, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TROGARZO, TRULANCE, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error